Abstract
Introduction
This analysis examines the historical and forecast performance for AstraZeneca
in the Rx pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark AstraZeneca' s performance against key rivals in the prescription
pharmaceutical sector
- Assess the commercial impact of AstraZeneca' s recent movement into the
biologics market, spearheaded by its acquisition of MedImmune
- Analyse the exposure of AstraZeneca' s blockbuster portfolio to patent
expiration and generic competition through to 2014
| 
View Cart
